ASRT250117C500
- 0.40
- -0.05-11.11%
Assertio Newsroom
H.C. Wainwright Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $4
Assertio Holdings Analyst Ratings
Promising Buy Rating for Assertio Therapeutics Backed by Positive ROLVEDON Trial Results and Market Potential
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Lake Street Sticks to Its Buy Rating for Assertio Therapeutics (ASRT)
Assertio Holdings Analyst Ratings
H.C. Wainwright Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $4
Assertio Therapeutics: Strong Buy Rating Backed by Robust Margins and Strategic Revenue Growth
Maxim Group Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
A. G. P. Maintains Assertio(ASRT.US) With Buy Rating, Cuts Target Price to $2.15
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Assertio Therapeutics (ASRT) Receives a Buy From Lake Street
Lake Street Maintains Assertio(ASRT.US) With Buy Rating, Maintains Target Price $3
Assertio Therapeutics: Strong Buy Rating on Robust Portfolio and Strategic Growth
Assertio Holdings Analyst Ratings
Maxim Group Initiates Assertio(ASRT.US) With Buy Rating, Announces Target Price $3
H.C. Wainwright Starts Assertio at Buy, Calls Stock Underrated, Overlooked
Assertio Holdings Analyst Ratings